This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vivecon

Myrexis, Inc.

Drug Names(s): MPC-9055

Description: Vivecon is a small-molecule maturation inhibitor. Vivecon targets a unique cleavage event in the HIV life cycle, inhibiting the processing of a Capsid-Spacer 1 intermediate of the Gag protein. This results in a noninfectious virion, and prevents subsequent rounds of HIV infection.

Deal Structure: In October 2008, Myriad Genetics announced that its Board of Directors has authorized management to proceed with preparations to spin off its research and drug development businesses from its molecular diagnostics business to form two independent public companies. The molecular diagnostics business will operate under the name Myriad Genetics, Inc., and the research and drug development businesses will operate under the name Myriad Pharmaceuticals, Inc.

In July 2009, Myriad Genetics announced the successful completion of the spin off of Myriad Pharmaceuticals.


Vivecon News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug